{"disease":{"id":"nlrc4-mas","name":"nlrc4 mas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02974595","title":"Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)","phase":"","overall_status":"RECRUITING","enrollment_count":3200,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03113760","title":"Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"AB2 Bio Ltd.","has_results":true},{"nct_id":"NCT03512314","title":"Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"AB2 Bio Ltd.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}